{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:21:41Z","timestamp":1786980101957,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Objectives: To determine the rate skin color is reported in randomized controlled trials (RCTs) involving basal cell carcinoma (BCC) identification and treatment in the top ten dermatology journals. Methods: A systematic review was conducted of RCTs involving BCC among the top ten dermatology journals, determined by impact factor, from inception to July 11th, 2023. Studies were included if they reviewed the prevention, detection, and treatment of BCC, directly involved patients, and were classified as RCTs. Studies were classified as positive for reporting skin of color (SOC) if the demographic data in the methods or results included any of the following terms: Fitzpatrick scale, race, ethnicity, skin of color, or sunburn tendency. Results: Of the 51 studies identified, only 23 articles reported data pertaining to skin color within the results section\u00a0(45.1%); whereas 28 articles mentioned skin color somewhere within the text (54.9%). Subgroup analysis was performed, and no statistical significance was found for study location or year of publication. Conclusion: Dark skin color can make it more difficult to diagnose skin tumors and it is unknown if race affects response to treatment. Less than 50% of RCTs related to basal cell carcinoma in top international dermatology journals included skin color within the demographic portion of their results section pertaining to study participants. Subgroup analysis demonstrated that studies performed within the United States reported skin color less than half the time (40%). Additionally, there has been no statistically significant difference in reporting over the past 4 decades. Further research is necessary to determine whether low reporting rates of race\/skin color in BCC-related RCTS could impact diagnostic or treatment recommendations for patient care in this group.<\/jats:p>","DOI":"10.1007\/s00403-024-03187-7","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T05:02:07Z","timestamp":1720155727000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Skin color reporting in basal cell carcinoma-related randomized controlled trials in top dermatology journals: a systematic review"],"prefix":"10.1007","volume":"316","author":[{"given":"Natasha L.","family":"Salmen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deven P.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony N.","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Willets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Brodell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,5]]},"reference":[{"issue":"1","key":"3187_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.hoc.2018.09.004","volume":"33","author":"DP Kim","year":"2019","unstructured":"Kim DP, Kus KJB, Ruiz E (2019) Basal cell Carcinoma Review. Hematol Oncol Clin N Am 33(1):13\u201324. https:\/\/doi-org.neomed.idm.oclc.org\/https:\/\/doi.org\/10.1016\/j.hoc.2018.09.004","journal-title":"Hematol Oncol Clin N Am"},{"key":"3187_CR2","unstructured":"Basal (2024), January 8 cell carcinoma. The Skin Cancer Foundation. https:\/\/www.skincancer.org\/skin-cancer-information\/basal-cell-carcinoma\/"},{"key":"3187_CR3","unstructured":"McDaniel B, Badri T, Steele RB Basal Cell Carcinoma. [Updated 2022 Sep 19]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482439\/"},{"key":"3187_CR4","doi-asserted-by":"publisher","first-page":"3098940","DOI":"10.1155\/2018\/3098940","volume":"2018","author":"ST Tan","year":"2018","unstructured":"Tan ST, Ghaznawie M, Heenan PJ, Dosan R (2018) Basal cell carcinoma arises from interfollicular layer of Epidermis. J Oncol 2018:3098940. https:\/\/doi.org\/10.1155\/2018\/3098940","journal-title":"J Oncol"},{"issue":"6 Suppl 1","key":"3187_CR5","first-page":"S17","volume":"15","author":"AM Sangha","year":"2022","unstructured":"Sangha AM (2022) Dermatological conditions in SKIN OF COLOR-A look at skin Cancer in skin of Color. J Clin Aesthetic Dermatol 15(6 Suppl 1):S17\u2013S18","journal-title":"J Clin Aesthetic Dermatol"},{"issue":"11","key":"3187_CR6","doi-asserted-by":"publisher","first-page":"adv00140","DOI":"10.2340\/00015555-3495","volume":"100","author":"N Basset-Seguin","year":"2020","unstructured":"Basset-Seguin N, Herms F (2020) Update in the management of basal cell carcinoma. Acta dermato-venereologica 100(11):adv00140. https:\/\/doi.org\/neomed.idmhttps:\/\/doi.org\/10.2340\/00015555-3495","journal-title":"Acta dermato-venereologica"},{"key":"3187_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00403-024-02843-2","volume":"316","author":"NL Salmen","year":"2024","unstructured":"Salmen NL, Menage K, Baumann AN et al (2024) Skin color reporting in squamous cell carcinoma-related randomized controlled trials in top dermatology journals: a systematic review. Arch Dermatol Res 316:115. https:\/\/doi.org\/10.1007\/s00403-024-02843-2","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"3187_CR8","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1002\/ski2.40","volume":"1","author":"P Goon","year":"2021","unstructured":"Goon P, Banfield C, Bello O, Levell NJ (2021) Skin cancers in skin types IV-VI: does the Fitzpatrick scale give a false sense of security? Skin Health Disease 1(3):e40. https:\/\/doi.org\/10.1002\/ski2.40","journal-title":"Skin Health Disease"},{"issue":"4","key":"3187_CR9","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.jaad.2014.05.023","volume":"71","author":"SY He","year":"2014","unstructured":"He SY, McCulloch CE, Boscardin WJ, Chren MM, Linos E, Arron ST (2014) Self-reported pigmentary phenotypes and race are significant but incomplete predictors of Fitzpatrick skin phototype in an ethnically diverse population. J Am Acad Dermatol 71(4):731\u2013737. https:\/\/doi.org\/10.1016\/j.jaad.2014.05.023","journal-title":"J Am Acad Dermatol"},{"key":"3187_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1600-0781.1999.tb00095.x","volume":"15","author":"JHTK Lee","year":"1999","unstructured":"Lee JHTK (1999) Relationship between constitutive skin color and ultraviolet light sensitivity in koreans. PhotoDermatol PhotoImmunol PhotoMed 15:231\u2013235","journal-title":"PhotoDermatol PhotoImmunol PhotoMed"},{"key":"3187_CR11","unstructured":"Park SB, Suh DH, Youn JI Reliability of self-assessment in determining skin phototype for Korean brown skin. Photodermatology, photoimmunology & photomedicine"},{"key":"3187_CR12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1600-0846.2008.00306.x","volume":"14","author":"G Sanclemente","year":"2008","unstructured":"Sanclemente G, Zapata JF, Garcia JJ, Gaviria A, Gomez LF, Barrera M (2008) Lack of correlation between minimal erythema dose and skin phototype in a Colombian scholar population. Skin Res Technol 14:403\u2013409","journal-title":"Skin Res Technol"},{"issue":"2","key":"3187_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.12788\/jhm.3650","volume":"17","author":"J Gau","year":"2022","unstructured":"Gau J, Nwora C, Eldakar-Hein ST, Goel MS, Lahey T, Repp AB (2022) Things we do for no Reason\u2122: routine inclusion of race in the history of present illness. J Hosp Med 17(2):123\u2013126. https:\/\/doi.org\/10.12788\/jhm.3650","journal-title":"J Hosp Med"},{"issue":"3","key":"3187_CR14","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1001\/jamainternmed.2020.5792","volume":"181","author":"JR Balderston","year":"2021","unstructured":"Balderston JR, Gertz ZM, Seedat R, Rankin JL, Hayes AW, Rodriguez VA, Golladay GJ (2021) Differential Documentation of Race in the First line of the history of Present Illness. JAMA Intern Med 181(3):386\u2013388. https:\/\/doi-org.neomed.idmhttps:\/\/doi.org\/10.1001\/jamainternmed.2020.5792","journal-title":"JAMA Intern Med"},{"key":"3187_CR15","doi-asserted-by":"publisher","unstructured":"Brett A, Goodman C (2021) December 25). First impressions \u2014 should we include race or ethnicity at the beginning of clinical case presentations? https:\/\/doi.org\/10.1056\/NEJMp2112312. https:\/\/www.nejm.org\/doi\/full\/","DOI":"10.1056\/NEJMp2112312"},{"issue":"1","key":"3187_CR16","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1177\/00221465231190061","volume":"65","author":"TM Cruz","year":"2024","unstructured":"Cruz TM (2024) Racing the machine: Data Analytic Technologies and Institutional Inscription of Racialized Health Injustice. J Health Soc Behav 65(1):110\u2013125. https:\/\/doi.org\/neomed.idmhttps:\/\/doi.org\/10.1177\/00221465231190061","journal-title":"J Health Soc Behav"},{"issue":"6","key":"3187_CR17","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s11606-015-3245-2","volume":"30","author":"MH Chin","year":"2015","unstructured":"Chin MH (2015) Using patient race, ethnicity, and language data to achieve health equity. J Gen Intern Med 30(6):703\u2013705. https:\/\/doi-org.neomed.idm.oclchttps:\/\/doi.org\/10.1007\/s11606-015-3245-2","journal-title":"J Gen Intern Med"},{"issue":"1","key":"3187_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jamacardio.2023.4529","volume":"9","author":"SS Khan","year":"2024","unstructured":"Khan SS, Yancy CW (2024) Race, racism, and Risk-Implications of Social Determinants of Health in Cardiovascular Disease Prediction. JAMA Cardiol 9(1):63. https:\/\/doi.org\/10.1001\/jamacardio.2023.4529","journal-title":"JAMA Cardiol"},{"issue":"5","key":"3187_CR19","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1007\/s40615-016-0283-3","volume":"4","author":"M Maga\u00f1a L\u00f3pez","year":"2016","unstructured":"Maga\u00f1a L\u00f3pez M, Bevans M, Wehrlen L, Yang L, Wallen GR (2016) Discrepancies in race and ethnicity documentation: a potential barrier in identifying racial and ethnic disparities. J Racial Ethnic Health Disparities 4(5):812\u2013818 Advance online publication. https:\/\/doi-org.neomed.idm.oclchttps:\/\/doi.org\/10.1007\/s40615-016-0283-3","journal-title":"J Racial Ethnic Health Disparities"},{"issue":"4","key":"3187_CR20","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3390\/healthcare10040603","volume":"10","author":"MR Cullen","year":"2022","unstructured":"Cullen MR, Lemeshow AR, Russo LJ, Barnes DM, Ababio Y, Habtezion A (2022) Disease-Specific Health disparities: a targeted review focusing on race and ethnicity. Healthc (Basel Switzerland) 10(4):603. https:\/\/doi.org\/10.3390\/healthcare10040603","journal-title":"Healthc (Basel Switzerland)"},{"issue":"6","key":"3187_CR21","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.seizure.2011.02.003","volume":"20","author":"Q Wang","year":"2011","unstructured":"Wang Q, Zhou JQ, Zhou LM, Chen ZY, Fang ZY, Chen SD, Yang LB, Cai XD, Dai QL, Hong H, Wang HX (2011) Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. Seizure 20(6):446\u2013448. https:\/\/doi.org\/10.1016\/j.seizure.2011.02.003","journal-title":"Seizure"},{"issue":"5","key":"3187_CR22","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11017-023-09622-6","volume":"44","author":"L Lorusso","year":"2023","unstructured":"Lorusso L, Bacchini F (2023) The indispensability of race in medicine. Theor Med Bioeth 44(5):421\u2013434. https:\/\/doi.org\/10.1007\/s11017-023-09622-6","journal-title":"Theor Med Bioeth"},{"issue":"2","key":"3187_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1001\/jamadermatol20164129","volume":"153","author":"A Charrow","year":"2017","unstructured":"Charrow A, Xia FD, Joyce C, Mostaghimi A (2017) Diversity in Dermatology clinical trials: a systematic review. JAMA Dermatology 153(2):193\u2013198. https:\/\/doi-org.neomed.idm.oclchttps:\/\/doi.org\/10.1001\/jamadermatol.2016.4129","journal-title":"JAMA Dermatology"},{"issue":"8","key":"3187_CR24","doi-asserted-by":"publisher","first-page":"e2331316","DOI":"10.1001\/jamanetworkopen.2023.31316","volume":"6","author":"LK Lee","year":"2023","unstructured":"Lee LK, Narang C, Rees CA, Thiagarajan RR, Melvin P, Ward V, Bourgeois FT (2023) Reporting and representation of participant race and ethnicity in National institutes of Health-Funded Pediatric clinical trials. JAMA Netw open 6(8):e2331316. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.31316","journal-title":"JAMA Netw open"},{"issue":"5","key":"3187_CR25","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/s0277-9536(00)00178-7","volume":"52","author":"VS Freimuth","year":"2001","unstructured":"Freimuth VS, Quinn SC, Thomas SB, Cole G, Zook E, Duncan T (2001) African americans\u2019 views on research and the Tuskegee Syphilis Study. Soc Sci Med 52(5):797\u2013808. https:\/\/doi.org\/10.1016\/s0277-9536(00)00178-7","journal-title":"Soc Sci Med"},{"issue":"5","key":"3187_CR26","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.cpcardiol.2018.11.002","volume":"44","author":"LT Clark","year":"2019","unstructured":"Clark LT, Watkins L, Pi\u00f1a IL, Elmer M, Akinboboye O, Gorham M, Jamerson B, McCullough C, Pierre C, Polis AB, Puckrein G, Regnante JM (2019) Increasing diversity in clinical trials: overcoming critical barriers. Curr Probl Cardiol 44(5):148\u2013172. https:\/\/doi.org\/10.1016\/j.cpcardiol.2018.11.002","journal-title":"Curr Probl Cardiol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03187-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03187-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03187-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T16:37:50Z","timestamp":1725899870000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03187-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,5]]},"references-count":26,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["3187"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03187-7","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,5]]},"assertion":[{"value":"2 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Robert Brodell, M.D. discloses the following potential conflicts of interest: Advisory boards: Novan and Amgen. Research funding: Pfizer, Novartis, and Sanofi. Stock: Veragen, Inc. Natasha Salmen, Deven Curtis, Anthony Baumann, and Jared Willets have no conflicts to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}],"article-number":"451"}}